Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT 3-armed trial	314 people	Change from baseline in least squares mean of Simpson-Angus Scale –0.5 with quetiapine (mean daily dose during monotherapy phase of trial 690.9 mg) 0.4 with paliperidone (mean daily dose during monotherapy phase of trial 10.4 mg)	P <0.05	Effect size not calculated	quetiapine
RCT 3-armed trial	314 people	Use of antiparkinsonism medication 37% with quetiapine (mean daily dose during monotherapy phase of trial 690.9 mg) 58% with paliperidone (mean daily dose during monotherapy phase of trial 10.4 mg) Absolute numbers not reported	P <0.05	Effect size not calculated	quetiapine
RCT 3-armed trial	314 people	Change from baseline in least squares mean of prolactin value, men –5.8 with quetiapine (mean daily dose during monotherapy phase of trial 690.9 mg) 19.2 with paliperidone (mean daily dose during monotherapy phase of trial 10.4 mg)	P <0.05	Effect size not calculated	quetiapine
RCT 3-armed trial	314 people	Change from baseline in least squares mean of prolactin value, women –16.1 with quetiapine (mean daily dose during monotherapy phase of trial 690.9 mg) +74.4 with paliperidone (mean daily dose during monotherapy phase of trial 10.4 mg)	P <0.05	Effect size not calculated	quetiapine
RCT 3-armed trial	314 people	Change from baseline in least squares mean of weight (kg) 0.8 with quetiapine (mean daily dose during monotherapy phase of trial 690.9 mg) 0.4 with paliperidone (mean daily dose during monotherapy phase of trial 10.4 mg)	P <0.05	Effect size not calculated	paliperidone